Sigyn Therapeutics Enters Material Definitive Agreement
Ticker: SIGY · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1642159
| Field | Detail |
|---|---|
| Company | Sigyn Therapeutics, Inc. (SIGY) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $220,420, $621,000, $110,000, $275,000, $125,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
TL;DR
Sigyn Therapeutics signed a big deal on April 9th, reported April 16th.
AI Summary
On April 16, 2024, Sigyn Therapeutics, Inc. reported an entry into a material definitive agreement. The earliest event reported in relation to this agreement was on April 9, 2024. The company is incorporated in Delaware and its principal executive offices are located in San Diego, California.
Why It Matters
This filing indicates a significant new contract or partnership for Sigyn Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can introduce new risks and opportunities, the specifics of which are not detailed in this initial report.
Key Players & Entities
- Sigyn Therapeutics, Inc. (company) — Registrant
- April 16, 2024 (date) — Date of report
- April 9, 2024 (date) — Earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Sigyn Therapeutics?
The filing does not specify the nature of the material definitive agreement, only that one was entered into.
When was the material definitive agreement officially entered into?
The earliest event reported in relation to the agreement was on April 9, 2024.
What is the filing date for this 8-K report?
The filing date for this 8-K report is April 16, 2024.
Where are Sigyn Therapeutics' principal executive offices located?
Sigyn Therapeutics' principal executive offices are located at 2468 Historic Decatur Road, Suite 140, San Diego, California, 92106.
What is Sigyn Therapeutics' state of incorporation?
Sigyn Therapeutics is incorporated in Delaware.
Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-04-16 17:17:07
Key Financial Figures
- $220,420 — s") in an aggregate principal amount of $220,420 to Brio Capital Master Fund Ltd. ("Brio
- $621,000 — issued an aggregate principal amount of $621,000 to Osher Capital Partners, LLC ("Osher"
- $110,000 — and Osher agreed to amend an additional $110,000 and $275,000, respectively, of Debentur
- $275,000 — eed to amend an additional $110,000 and $275,000, respectively, of Debentures to extend
- $125,000 — principal amount of such Debentures to $125,000 and $316,350, respectively, and provide
- $316,350 — ount of such Debentures to $125,000 and $316,350, respectively, and provide for the auto
- $1,856,566 — the automatic conversion of a total of $1,856,566 aggregate principal amount of Debenture
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-24-014866.txt ( ) — 204KB
- sigy-20240416.xsd (EX-101.SCH) — 3KB
- sigy-20240416_lab.xml (EX-101.LAB) — 33KB
- sigy-20240416_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGYN THERAPEUTICS, INC. Date: April 16, 2024 By: /s/ James A. Joyce James A. Joyce, Chairman and CEO